XML 66 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Deferred Revenue - Additional Information (Detail)
$ / shares in Units, € in Thousands, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 13, 2018
USD ($)
$ / shares
Feb. 28, 2017
USD ($)
Jan. 23, 2017
EUR (€)
shares
Jan. 23, 2017
USD ($)
shares
Feb. 28, 2018
EUR (€)
Feb. 28, 2018
USD ($)
Jan. 31, 2017
USD ($)
Jun. 30, 2018
EUR (€)
shares
Jun. 30, 2018
EUR (€)
shares
Jun. 30, 2018
USD ($)
$ / shares
Jun. 30, 2017
EUR (€)
 [1]
Jun. 30, 2018
USD ($)
shares
Dec. 31, 2017
EUR (€)
Disclosure of deferred income [line items]                          
Total deferred revenue               € 122,690 € 122,690       € 128,486
Purchase price per share | $ / shares $ 18.00                        
Aggregate purchase price $ 55,800       € 44,800 $ 55,800 $ 80,000   44,731   € 74,431    
Non-refundable upfront payment received | $   $ 120,000                      
Upfront and Milestone Payments [member]                          
Disclosure of deferred income [line items]                          
Revenue recognized               € 300 € 300        
Incyte Corporation [member]                          
Disclosure of deferred income [line items]                          
Non-refundable upfront payment receivable | $                       $ 120,000  
Common shares issued | shares     3,200,000 3,200,000       3,200,000 3,200,000     3,200,000  
Purchase price per share | $ / shares                   $ 25.00      
Aggregate purchase price     € 74,700 $ 80,000           $ 80,000      
Remaining estimated amortization period                 7 years 6 months 7 years 6 months      
Incyte Corporation [member] | Deferred revenue [member]                          
Disclosure of deferred income [line items]                          
Non-refundable upfront payment received                 € 112,000        
Fair value of derivatives               € 31,400 31,400        
Incyte collaboration agreement [member]                          
Disclosure of deferred income [line items]                          
Total deferred revenue               120,600 120,600        
Simcere collaboration and license agreement [member]                          
Disclosure of deferred income [line items]                          
Total deferred revenue               2,000 2,000        
Non-refundable upfront payment received                 2,300 $ 2,750      
ONO Research and License Agreement [member]                          
Disclosure of deferred income [line items]                          
Total deferred revenue               100 100        
Performance obligation recognized as revenue               € 100 1,100        
Paid for full time equivalent funding                 200        
Compensate for research service                 300        
ONO Research and License Agreement [member] | Deferred revenue [member]                          
Disclosure of deferred income [line items]                          
Non-refundable upfront payment received                 € 700        
[1] See Note 3 for details regarding the restatement as a result of a change in accounting policy.